MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.850
+0.050
+1.32%
After Hours: 3.890 +0.04 +1.04% 17:46 06/11 EDT
OPEN
3.820
PREV CLOSE
3.800
HIGH
3.890
LOW
3.800
VOLUME
160.56K
TURNOVER
--
52 WEEK HIGH
9.84
52 WEEK LOW
2.530
MARKET CAP
36.53M
P/E (TTM)
-0.2525
1D
5D
1M
3M
1Y
5Y
Acorda Therapeutics Granted U.S. Patent Titled 'Water-soluble acetaminophen analogs'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=acorda&OS=acorda&RS=acorda
Benzinga · 06/01 19:04
US Pain Relief Therapeutics Market Share 2021 : Growth Opportunities with Covid-19 Impact Analysis, Business Structure with Top Key Players Size, Development Plans and Challenges Forecast to 2027
The rising prevalence of chronic diseases such as a variety of cancers, osteoarthritis, stomach ulcer, chronic arthritis and diabetes are major key factor which drives the Global Pain Relief Therapeutics Market.
Heraldkeepers · 05/26 07:34
Why Investors in Acorda Therapeutics #ACOR Consider Price Action to be a Tell
May 12, 2021 (Stock Traders Daily via COMTEX) -- A tell is a precursor of a stock's next move, and #investors in Acorda Therapeutics (NASDAQ: ACOR) look for...
Stock Traders Daily · 05/12 12:55
Spinal Cord Trauma Treatment Market Size 2021 Industry Recent Developments and Latest Technology, Size, Trends, Global Growth, Supply Demand Scenario, and Forecast Research Report 2027
May 12, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Spinal Cord Trauma Treatment...
The Express Wire · 05/12 10:02
Non-opioid Pain Patch Market Size Report 2021 to 2027: Strategies of Key Manufacturers, New Project Investment
May 11, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" “Non-opioid Pain Patch Market” Report 2021...
The Express Wire · 05/11 10:34
Multiple Sclerosis Therapeutics Market Outlook 2025, Size, Forecasts, Demand, Competitive Analysis, Growth Factors, Key Players
Japan, Japan, Fri, 07 May 2021 05:38:39 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 05/07 09:40
8-K: ACORDA THERAPEUTICS INC
(EDGAR Online via COMTEX) -- false 0001008848 0001008848 2021-05-06 2021-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/06 21:42
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 05/06 21:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACOR. Analyze the recent business situations of Acorda through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACOR stock price target is 17.50 with a high estimate of 30.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 189
Institutional Holdings: 6.37M
% Owned: 67.18%
Shares Outstanding: 9.49M
TypeInstitutionsShares
Increased
12
1.16M
New
11
383.53K
Decreased
13
938.61K
Sold Out
21
125.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Non-Executive Chairman/Independent Director
John Kelley
Chief Executive Officer/President/Director
Ron Cohen
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Controller
Robert Morales
Other
Burkhard Blank
Other
Lauren Sabella
Independent Director
Peder Jensen
Independent Director
Sandra Panem
Independent Director
Lorin Randall
No Data
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.